Document:

Exhibit 10.4

 

MODINE MANUFACTURING COMPANY

2017 INCENTIVE COMPENSATION PLAN

NON-QUALIFIED STOCK OPTION

AWARD AGREEMENT

We are pleased to inform you that you have been granted an Option to purchase shares of Common Stock of Modine Manufacturing Company (the “Company”), subject to the terms and conditions of the Modine Manufacturing Company 2017 Incentive Compensation Plan (the “Plan”) and of this Award Agreement.  Unless otherwise defined herein, all terms used in this Award Agreement shall have the same meanings as set forth in the Plan.

 

	
Full name of Grantee:

	 
	 	 
	
Date of Award:

	
May 30, 2018

	 	 
	
Exercise price per share:

	 
	 	 
	
Total number of shares:

	 
	 	 
	
Total exercise price:

	 

1.    Option.  Pursuant to the Plan, you are hereby granted the option to purchase shares of Common Stock on the terms and conditions set forth in this Award Agreement.  The Option granted hereunder shall be a Non-Qualified Stock Option.

2.    Vesting Schedule.  The Option granted pursuant to this Award will vest according to the following schedule, provided, however, that, except as otherwise provided in Section 12.02 of the Plan or in this Award Agreement, you must be employed by the Company or a Subsidiary on each vesting date for that portion of the Option to vest.  If you separate from service due to Disability (as defined below), death, or your retirement (with Committee approval) prior to any Vesting Date, any unvested portion of the Option shall become fully and immediately exercisable.  For purposes of this Award Agreement, “Disability” shall mean “permanent and total disability” as defined in Section 22 (e)(3) of the Code.

	
    Number of Shares of Common Stock

	
Vesting Date

	
25% of the total number of shares

	
May 30, 2019

	
25% of the total number of shares

	
May 30, 2020

	
25% of the total number of shares

	
May 30, 2021

	
25% of the total number of shares

	
May 30, 2022

3.    Time of Exercise; Exercise Limitation.  Vested Options may be exercised (in the manner provided in paragraph 4 hereof) in whole or in part, from time to time after the Vesting Date, subject to the following limitations:

 

		(a)	
Because you are an executive officer of the Company subject to the reporting requirements of Section 16 of the Securities Exchange Act of 1934, the Option may not be exercised by you within six (6) months after the Grant Date; and

		(b)	
The Option may only be exercised, at any one time, exclusively in multiples of twenty‐five (25) shares with a one hundred (100) share exercise minimum, except for the purchase of all shares then remaining subject to these options.

4.    Method of Exercising Option.  Subject to the limitations stated elsewhere in this Award Agreement or in the Plan, this Option will be exercisable as to all or a portion of the Common Stock in accordance with the vesting schedule above in Paragraph 2.  In no event will the Option be exercisable if it would result in a violation of federal or state securities laws or would occur later than ten (10) years from the date of grant.  The Option may be exercised in whole or in part by delivery to the Company or its designee of (a) written notice identifying the Option and stating the number of shares with respect to which it is being exercised, and (b) payment in full of the exercise price of the shares then being acquired; provided, however, that you may pay the exercise price either in cash, by transferring to the Company shares of stock of the Company at their Fair Market Value as of the date of exercise of the Option ("Delivered Stock"), a combination of cash and Delivered Stock, or such other forms or means that the Company determines are consistent with the Plan's purpose and applicable law.  Notwithstanding the foregoing, the Company may arrange for or cooperate in permitting broker-assisted cashless exercise procedures.  No person shall acquire any rights or privileges of a shareholder of the Company with respect to any shares of Common Stock until such shares have been duly issued.  The Company shall have the right to delay the issue or delivery of any shares to be delivered hereunder until (a) the completion of such registration or qualification of such shares under federal, state or foreign law, ruling or regulation as the Company shall deem to be necessary or advisable, and (b) receipt from you of such documents and information as the Company may deem necessary or appropriate in connection with such registration or qualification or the issuance of shares hereunder.

 

5.    Expiration Date.  Upon a termination of your employment for any reason (except termination of employment for Cause), this Option shall expire one (1) year from the date of termination of your employment.  Upon your termination of employment for Cause, this Option shall immediately expire. Notwithstanding anything herein contained to the contrary, this Option shall not be exercisable subsequent to ten (10) years after the date of grant.

 

6.    Transfer.  The Option shall be nontransferable and shall, except in the case of death or Disability, be exercisable only by you during your lifetime.  Notwithstanding the foregoing, you shall have the right to transfer the Option upon your death, either by the terms of your will or under the laws of descent and distribution.  In the case of your Disability, the Option shall be exercisable by your personal representative.  Upon your death, the Option shall be exercisable by your personal representative, administrator, or other representative of your estate, or the person or persons to whom this Option shall pass by will or under the laws of descent and distribution.

 

7.    No Unlawful Issue of Shares.  If, in the opinion of its counsel, the issue or sale of any shares of its stock hereunder pursuant to the Option shall not be lawful for any reason, including the inability of the Company to obtain, from any regulatory body having jurisdiction, authority deemed by such counsel to be necessary to such issuance or sale, the Company shall not be obligated to issue or sell any such shares pursuant to the exercise of the Option.

 

2

8.    No Obligation of Employment.  The Option shall not impose any obligation on the Company to continue your employment with the Company or a Subsidiary.

 

9.    Controlling Provisions; Plan Controls.  In the event of a conflict between the terms of this Award Agreement and any employment agreement or change in control agreement between you and the Company, this Award Agreement shall control.  This Option is qualified in its entirety by reference to the terms and conditions of the Plan under which it is granted, a copy of which you may request from the Company.  The Plan empowers the Committee to make interpretations, rules and regulations thereunder and, in general, provides that the determinations of such Committee with respect to the Plan shall be binding upon you.  The Plan is hereby incorporated herein by reference.

 

10.  Change in Control.  The vesting of the Option in the event of a Change in Control is governed by Section 12.02 of the Plan.  Involuntary termination of your employment by the Company would be termination of your employment by the Company without Cause and termination by you of your employment for Good Reason.   “Good Reason” means a material diminution in your base salary; material diminution in your annual target bonus opportunity; material diminution in your authority, duties or responsibilities; material diminution in authority, duties or responsibilities of the supervisor to whom you report; material diminution in the budget over which you retain authority; or material change in the geographic location at which you must perform services.

 

11.  Forfeiture Under Recoupment Policy.  The Company shall have the power and the right to require you to forfeit this Option, return the shares of Common Stock issued pursuant to an exercise of this Option or any proceeds therefrom consistent with any recoupment policy maintained by the Company under applicable law, as such policy is amended from time to time.

 

12.  Use of Words.  The use of words of the masculine gender in this Award Agreement is intended to include, wherever appropriate, the feminine or neuter gender and vice versa.

13.  Successors.  This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company.

14.  Taxes.  The Company may require payment of or withhold any tax that it believes is required as a result of the grant or exercise of the Option, and the Company may defer making delivery with respect to shares issuable hereunder until arrangements satisfactory to the Company have been made with respect to such tax withholding obligations.

15.  Personal Information.  Solium Capital LLC and Equiniti Trust Company assist the Company in the operation of the Plan and the administration of the Option granted pursuant to this Award Agreement.  If you choose to participate in the Plan, you acknowledge and consent to the Company sharing your name, email, and information regarding the grant of the Option under this Award Agreement with both Solium Capital LLC and Equiniti Trust Company.

By your electronic agreement and the signature of the Company’s representative below, you and the Company agree that the Option which has been awarded to you under this Award Agreement is subject to the terms and conditions of the Plan, a copy of which is available to you upon request.  As provided in the Plan, you hereby agree to accept as binding any decision of the Committee with respect to the interpretation of the Plan and this Award Agreement, or any other matters associated therewith.

 

3

IN WITNESS WHEREOF, the Company has caused this Award Agreement to be executed as of May 30, 2018.

	 	
MODINE MANUFACTURING COMPANY

	 	 	 
	 	
By:

	
/s/ Thomas A. Burke

	 	 	
Thomas A. Burke

	 	 	
President and Chief Executive Officer

 

 

4Exhibit 10.1

 

Execution Copy

 

WAIVER, CONSENT AND THIRD AMENDMENT TO
 NOTE PURCHASE AGREEMENT

AND PARTIAL RELEASE OF SECURITY INTEREST

 

THIS WAIVER, CONSENT AND THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT AND PARTIAL RELEASE OF SECURITY INTEREST, dated as of August 2, 2018 (this “Agreement”), is entered into by and among DEPOMED, INC., a California corporation (the “Borrower”), the other Credit Parties party hereto, the Purchasers party hereto, and DEERFIELD PRIVATE DESIGN FUND III, L.P., a Delaware limited partnership, as a Purchaser and as collateral agent (in such latter capacity, the “Agent”).

 

BACKGROUND STATEMENT

 

A.                                    The Borrower, the Purchasers and the Agent entered into that certain Note Purchase Agreement, dated as of March 12, 2015, as amended by that certain Consent and First Amendment to Note Purchase Agreement, dated as December 29, 2015, and that Waiver and Second Amendment to Note Purchase Agreement, dated as December 4, 2017 (as the same may be amended, modified, restated or otherwise supplemented from time to time, the “Purchase Agreement”), pursuant to which the Borrower issued up to $575,000,000 aggregate principal amount of secured notes to the Purchasers.  Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Purchase Agreement.

 

B.                                    The Borrower wishes to enter into that certain Amendment No. 1 to Royalty Purchase and Sale Agreement and Bill of Sale, to be dated on or around the date hereof (the “PDL Amendment”), among the Borrower, Depo DR and PDL Investment Holdings, Inc., a Delaware corporation, as assignee of PDL Biopharma, Inc.  (“PDLIH”), relating to the PDL Royalty Agreement and pursuant to which the Borrower and Depo DR will sell their rights in the Reversionary Interest (as defined in the PDL Royalty Agreement prior to the effectiveness of the PDL Amendment) to PDLIH.

 

C.                                    As a condition precedent to the effectiveness of the PDL Amendment, the Borrower is required to cause the Agent to release its security interest in any Lien granted to the Agent on the Reversionary Interest or the Capital Stock of Depo DR.

 

D.                                    The Borrower wishes to make an Investment in NES Therapeutics, Inc., a Delaware corporation (“NEST”).

 

E.                                     The Borrower has requested that the Purchasers consent to the Borrower and, to the extent applicable, Depo DR (1) entering into the PDL Amendment (and, in connection therewith, amending Section 6.9 of the Purchase Agreement, waiving the requirement that some or all of the Asset Disposition Proceeds realized from the PDL Amendment be used to prepay the outstanding principal amount of the Notes pursuant to Section 2.7(b) of the Purchase Agreement and releasing the Agent’s security interest in the equity interests of Depo DR) and (2) making the NEST Investment.

 

F.                                      The Purchasers party hereto, which constitute the Required Purchasers as required by Section 9.10 of the Purchase Agreement, are willing to provide the aforementioned consents,

 

 

amendment, waiver and release in accordance with, and subject to, the terms and conditions set forth herein.

 

STATEMENT OF AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE I

 

ACKNOWLEDGMENT; WAIVER

 

1.1                               Subject to the terms and conditions hereof, the Purchasers party hereto, which constitute the Required Purchasers as required by Section 9.10 of the Purchase Agreement, hereby waive the requirement that the Borrower use all or any portion of the Asset Disposition Proceeds received pursuant to the terms of the PDL Amendment to prepay any portion of the outstanding principal amount of the Notes pursuant to Section 2.7(b) of the Purchase Agreement.

 

1.2                               The waiver set forth in Section 1.1 is only with respect to the PDL Amendment in substantially the form provided to the Agent’s counsel at 9:00 p.m. (EDT) on August 1, 2018, and if any amendment, modification or supplement is made to the PDL Amendment or if any waiver is granted by any party thereto from compliance with the terms thereof, in each case, in a manner that could reasonably be expected to adversely affect the Purchasers in any material respect without the written consent of the Required Purchasers such waiver shall be rendered null and void ab initio.

 

ARTICLE II

 

CONSENTS; AMENDMENT; PARTIAL RELEASE OF SECURITY INTEREST

 

2.1                               Subject to the terms and conditions hereof, the Purchasers party hereto, which constitute the Required Purchasers as required by Section 9.10 of the Purchase Agreement, and the Agent hereby consent to:

 

(a)                                 The entry by the Borrower and, to the extent applicable, Depo DR into the PDL Amendment in substantially the form provided to the Agent’s counsel at 9:00 p.m. (EDT) on August 1, 2018;

 

(b)                                 The making by the Borrower of an Investment in NEST in the form of a senior unsubordinated secured note with an aggregate principal amount not to exceed $3,000,000 (the “NEST Investment”);

 

(c)                                  The release of the Agent’s security interest in the Reversionary Interest and the Capital Stock of Depo DR;

 

(d)                                 The definition of “Subsidiary” in Section 1.1 of the Purchase Agreement is hereby amended by adding the following as the last sentence thereof:  “Notwithstanding anything herein

 

2

 

to the contrary, Depo DR shall not be a Subsidiary of the Borrower or any other Credit Party for any purpose under the Credit Documents.”; and

 

(e)                                  Section 6.9 of the Purchase Agreement is hereby amended and restated in its entirety as follows: “[Reserved.]”

 

2.2                               Subject to the terms and conditions hereof, any Liens on the Reversionary Interest and the Capital Stock of Depo DR in favor of the Agent, for the benefit of the Purchasers, to secure the Obligations are hereby released by the Agent without representation, warranty or recourse.

 

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES

 

To induce the Purchasers to enter into this Agreement, the Borrower hereby represents and warrants to the Agent and the Purchasers as follows:

 

3.1                               Representations and Warranties.  Both immediately before and after giving effect to this Agreement and the transactions contemplated hereby, each of the representations and warranties of each Credit Party contained in the Purchase Agreement and each other Credit Document is true and correct in all material respects on and as of the date hereof with the same effect as if made on and as of the date hereof (except to the extent any such representation or warranty is expressly stated to have been made as of a specific date, in which case such representation or warranty was true and correct as of such date).

 

3.2                               No Default.  Both immediately before and after giving effect to this Agreement and the transactions contemplated hereby, no Default or Event of Default has occurred and is continuing.

 

3.3                               Authorization; Approvals.  The execution, delivery and performance of this Agreement and the transactions contemplated hereby (a) are within the corporate or limited liability company authority, as applicable, of each Credit Party, (b) have been duly authorized by all necessary corporate or limited liability company action, as applicable, of each Credit Party, (c) do not and will not contravene any other Requirement of Law to which any Credit Party is subject or any judgment, order, writ, injunction, license or permit applicable to any Credit Party,  and (d) do not violate or breach any provision of the governing documents of any Credit Party or any agreement or other instrument binding upon any Credit Party. The execution, delivery and performance of this Agreement by each Credit Party does not require the approval or consent of, or filing with, any Governmental Authority.

 

3.4                               Enforceability.  This Agreement has been duly executed and delivered by each Credit Party and constitutes each Credit Party’s legal, valid and binding obligation, enforceable in accordance with its terms, except as such enforceability may be limited by bankruptcy, reorganization, insolvency, moratorium or other similar laws affecting creditors’ rights generally or by general equitable principles.

 

3

 

3.5                               Material Non-Public Information. As of 8:30 a.m. on the Business Day immediately following the date on which the Borrower has entered into the PDL Amendment, it has disclosed all material, non-public information (if any) provided or made available to any Restricted Purchaser (or any such Restricted Purchaser’s agents or representatives) on or prior to such date by it or any of its respective officers, directors, employees, Affiliates or agents in connection with the transactions contemplated by this Agreement, the PDL Amendment or otherwise.

 

ARTICLE IV

 

EFFECTIVENESS

 

4.1                               This Agreement shall become effective as of the date when, and only when, each of the following conditions precedent shall have been satisfied (such date, the “Effective Date”):

 

(a)                                 The Agent shall have received an executed counterpart of this Agreement from each Credit Party and Purchasers constituting each of the Required Purchasers.

 

(b)                                 The Borrower shall have paid all expenses due in accordance with Section 8.1 hereof.

 

(c)                                  Both immediately before and after giving effect to this Agreement and the transactions contemplated hereby, each of the representations and warranties contained in this Agreement shall be true and correct in all material respects on and as of the Effective Date, with the same effect as if made on and as of such date.

 

(d)                                 The Agent shall have received a fully executed copy of the PDL Amendment in the form provided to the Agent’s counsel at 9:00 p.m. (EDT) on August 1, 2018 with only such amendments and modifications thereto as may have been specifically approved by the Required Purchasers.

 

(e)                                  The Required Purchasers shall have received such other documents, agreements, instruments, certificates or other confirmations as the Required Purchasers may reasonably request.

 

ARTICLE V

 

POST-EFFECTIVENESS OBLIGATIONS

 

5.1                               Within 10 days of the issuance thereof, the Borrower shall deliver to the Agent the originals of any certificates or Instruments issued to it in connection with the NEST Investment.

 

ARTICLE VI

 

SECURITIES ACT RELATED OBLIGATIONS

 

6.1                               On or before 8:00 a.m., New York time, on the Business Day immediately following the date on which the Borrower has entered into the PDL Amendment, the Borrower shall file a Current Report on Form 8-K (a) disclosing (i) the Borrower’s entry into the PDL

 

4

 

Amendment and (ii) all other material, non-public information (if any) provided or made available to any Restricted Purchaser (or any such Restricted Purchaser’s agents or representatives) on or prior to such date by Borrower or any of its respective officers, directors, employees, Affiliates or agents in connection with the transactions contemplated by this Amendment, the PDL Amendment or otherwise and (b) including this Agreement in its entirety as an exhibit thereto.  After giving effect to the filing required under this Section 6.1, the Borrower expressly acknowledges and agrees that no Restricted Purchaser and none of its agents or representatives shall have any duty of trust or confidence with respect to, or a duty not to trade on the basis of, any information provided by Borrower or any of its respective officers, directors, employees, Affiliates or agents in connection with the transactions contemplated by this Agreement, the PDL Amendment or otherwise.

 

6.2                               Either prior to the time that the Borrower files its Form 10-Q for the quarterly period ended June 30, 2018 or in conjunction with the filing thereof, the Borrower shall file the PDL Amendment in its entirety as an exhibit to a Current Report on Form 8-K or an as exhibit to such Form 10-Q.

 

ARTICLE VII

 

AFFIRMATION OF OBLIGATIONS

 

Each of the Credit Parties hereby acknowledges and consents to all of the terms and conditions of this Agreement and agrees that this Agreement and all documents executed in connection herewith do not operate to reduce or discharge such Credit Party’s obligations (as applicable) under the Purchase Agreement, the Guaranty, the Security Agreement and the other Credit Documents to which it is a party.  Further, each of the Credit Parties hereby (i) ratifies and confirms its pledge of and grant of a security interest in and Lien on all of its collateral to the Agent made pursuant to the Security Agreement and the other Credit Documents to which it is a party, which security interest and Lien shall continue in full force and effect without interruption, and shall constitute the single grant of a security interest and Lien, (ii) confirms and agrees that, after giving effect to this Agreement, the Purchase Agreement, the Guaranty, the Security Agreement and the other Credit Documents to which it is a party remain in full force and effect and enforceable against such Credit Party in accordance with their respective terms and shall not be discharged, diminished, limited or otherwise affected in any respect, and (iii) represents and warrants to the Agent and the Purchasers that it has no knowledge of any claims, counterclaims, offsets, or defenses to or with respect to its obligations under the Credit Documents, or if such Credit Party has any such claims, counterclaims, offsets, or defenses to the Credit Documents or any transaction related to the Credit Documents, the same are hereby waived, relinquished, and released in consideration of the execution of this Agreement.  Each of the Credit Parties further waives any defense to its guaranty liability occasioned by this Agreement.  This acknowledgement and confirmation by each of the Credit Parties is made and delivered to induce the Agent and the Purchasers to enter into this Agreement, and each Credit Party acknowledges that the Agent and the Purchasers would not enter into this Agreement in the absence of the acknowledgement and confirmation contained herein.

 

5

 

ARTICLE VIII

 

EXPENSES

 

8.1                               Expenses.  Whether or not the Effective Date occurs, the Borrower agrees, on demand, to pay all reasonable out-of-pocket costs and expenses of the Agent and each Purchaser (including, without limitation, reasonable fees and expenses of counsel) in connection with the preparation, negotiation, execution and delivery of this Agreement.

 

ARTICLE IX

 

MISCELLANEOUS

 

9.1                               Effect of Consent.  From and after the Effective Date, all references to the Purchase Agreement set forth in the Purchase Agreement and any other Credit Document or other agreement or instrument shall, unless otherwise specifically provided, be references to the Purchase Agreement as modified by this Agreement.  This Agreement is limited as specified and shall not constitute or be deemed to constitute an amendment, modification or waiver of any provision of the Purchase Agreement except as expressly set forth herein.  Nothing herein shall be deemed to entitle the Borrower or any other Credit Party or Person to a consent to, or a waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Purchase Agreement or any other Credit Document in similar or different circumstances.  For the avoidance of doubt, this Agreement shall be deemed a Credit Document.

 

9.2                               Governing Law.  This Agreement shall be governed by and construed and enforced in accordance with, the law of the State of New York (including Sections 5-1401 and 5-1402 of the New York General Obligations Law, but excluding all other choice of law and conflicts of law rules).

 

9.3                               Severability.  To the extent any provision of this Agreement is prohibited by or invalid under the applicable law of any jurisdiction, such provision shall be ineffective only to the extent of such prohibition or invalidity and only in any such jurisdiction, without prohibiting or invalidating such provision in any other jurisdiction or the remaining provisions of this Agreement in any jurisdiction.

 

9.4                               Successors and Assigns.  This Agreement shall be binding upon, inure to the benefit of and be enforceable by the respective successors and assigns of the parties hereto.

 

9.5                               Construction.  The headings of the various sections and subsections of this Agreement have been inserted for convenience only and shall not in any way affect the meaning or construction of any of the provisions hereof.

 

9.6                               Counterparts; Integration.  This Agreement may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of which when so executed and delivered shall be an original, but all of which shall together constitute one and the same instrument.  This agreement or any counterpart may be executed and delivered by facsimile or electronic mail, each of which shall be deemed an original. This Agreement and the other

 

6

 

Credit Documents constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.

 

[THE REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY]

 

7

 

IN WITNESS WHEREOF, the undersigned Agent, Purchasers, the Borrower and the other Credit Parties have caused this Agreement to be duly executed as of the date first above written.

 

	
 
    	
Borrower:
    
	
 
    	
 
    
	
 
    	
DEPOMED, INC.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Amar Murugan
    
	
 
    	
Name: Amar Murugan
    
	
 
    	
Title: Senior Vice   President and General Counsel
    
	
 
    	
 
    
	
 
    	
Other Credit Parties:
    
	
 
    	
 
    
	
 
    	
DEPO NF SUB, LLC
    
	
 
    	
 
    
	
 
    	
By:
    	
Depomed, Inc., its   sole member
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Amar Murugan
    
	
 
    	
Name: Amar Murugan
    
	
 
    	
Title: Senior Vice   President and General Counsel
    
					

 

 

	
 
    	
Agent   and Purchasers:
    
	
 
    	
 
    
	
 
    	
DEERFIELD PRIVATE DESIGN FUND   III, L.P., as Collateral Agent and a Purchaser
    
	
 
    	
 
    
	
 
    	
By:
    	
Deerfield Mgmt III,   L.P.
    
	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
J.E. Flynn Capital III,   LLC
    
	
 
    	
 
    	
 
    	
General Partner
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ David J. Clark
    
	
 
    	
Name: David J. Clark
    
	
 
    	
Title: Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
DEERFIELD PARTNERS, L.P.,   as a Purchaser
    
	
 
    	
 
    
	
 
    	
By:
    	
Deerfield Mgmt, L.P.
    
	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
J.E. Flynn Capital, LLC
    
	
 
    	
 
    	
 
    	
General Partner
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ David J. Clark
    
	
 
    	
Name: David J. Clark
    
	
 
    	
Title: Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
DEERFIELD INTERNATIONAL MASTER   FUND, L.P., as a Purchaser
    
	
 
    	
 
    
	
 
    	
By:
    	
Deerfield Mgmt, L.P.
    
	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
J.E. Flynn Capital, LLC
    
	
 
    	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ David J. Clark
    
	
 
    	
Name: David J. Clark
    
	
 
    	
Title: Authorized   Signatory
    
					

 

 

	
 
    	
DEERFIELD SPECIAL SITUATIONS   FUND, L.P., as a Purchaser
    
	
 
    	
 
    
	
 
    	
By:
    	
Deerfield Mgmt, L.P.
    
	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
J.E. Flynn Capital, LLC
    
	
 
    	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ David J. Clark
    
	
 
    	
Name: David J. Clark
    
	
 
    	
Title: Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
DEERFIELD PRIVATE DESIGN FUND   II, L.P., as a Purchaser
    
	
 
    	
 
    
	
 
    	
By:
    	
Deerfield Mgmt, L.P.
    
	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
J.E. Flynn Capital, LLC
    
	
 
    	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ David J. Clark
    
	
 
    	
Name: David J. Clark
    
	
 
    	
Title: Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
DEERFIELD PRIVATE DESIGN   INTERNATIONAL II, L.P., as a Purchaser
    
	
 
    	
 
    
	
 
    	
By:
    	
Deerfield Mgmt, L.P.
    
	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
J.E. Flynn Capital, LLC
    
	
 
    	
 
    	
 
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ David J. Clark
    
	
 
    	
Name: David J. Clark
    
	
 
    	
Title: Authorized   Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]